PKM2 As a Biomarker for Chemosensitivity to Front-line Platinum-based Chemotherapy in Patients with Metastatic Non-small-cell Lung Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2014 Sep 19

PMID 25233397

Citations 35

Authors

C Papadaki

M Sfakianaki

E Lagoudaki

G Giagkas

G Ioannidis

M Trypaki

E Tsakalaki

A Voutsina

A Koutsopoulos

D Mavroudis

V Georgoulias

J Souglakos

Affiliations

Soon will be listed here.

Abstract

Background: Tumour cells exclusively express the embryonic M2 isoform of pyruvate kinase (PKM2). PKM2 expression levels have been correlated with the effect of platinum compounds in cancer cell lines and xenograft models. The potential predictive role of PKM2 in patients with metastatic/advanced non-small-cell lung cancer (NSCLC) receiving platinum-based chemotherapy as first-line was investigated.

Methods: Quantitative real-time PCR was used to assess the expression of PKM2 in tumour samples from 148 and 157 NSCLC patients in the training and the validation set, respectively. All patients received front-line platinum-based chemotherapy. PKM2 mRNA expression was also analysed in a control group of 85 NSCLC patients treated with non-platinum containing regimens.

Results: In the training set, high PKM2 mRNA levels were associated with decreased progression-free survival (PFS; 4.9 months vs 6.4, P=0.006), overall survival (OS; 10.1 vs 17.0 months, P=0.01) and disease control rate (DCR; 57.7% vs 74.3%; P=0.021) compared to patients with low PKM2 levels. In the validation set, high PKM2 mRNA levels were also associated with deceased PFS (3.7 vs 5.9 months, P=0.006), OS (8.3 vs 16.8 months, P=0.003) and DCR (57.7% vs 70.9%; P=0.049) compared to those with low PKM2 mRNA levels. There was no correlation between the PKM2 mRNA levels and the PFS (5.6 vs 5.9, P=0.43) or the OS (9.8 vs 10.1, P=0.51) in the control group. Multivariate analysis revealed high PKM2 mRNA expression as an independent predictive factor for the poor patients' outcome.

Conclusions: PKM2 expression may be a predictive biomarker of platinum sensitivity in advanced NSCLC patients treated with platinum-based chemotherapy.

Citing Articles

The regulatory roles and clinical significance of glycolysis in tumor.

Qiao Q, Hu S, Wang X Cancer Commun (Lond). 2024; 44(7):761-786.

PMID: 38851859 PMC: 11260772. DOI: 10.1002/cac2.12549.

Imidazopyrimidine: from a relatively exotic scaffold to an evolving structural motif in drug discovery.

Chowdhury M, Kalmegh V, Kapoor S, Kamble V, Shard A RSC Med Chem. 2024; 15(5):1488-1507.

PMID: 38784469 PMC: 11110759. DOI: 10.1039/d3md00718a.

Modulating Glycolysis to Improve Cancer Therapy.

Chelakkot C, Chelakkot V, Shin Y, Song K Int J Mol Sci. 2023; 24(3).

PMID: 36768924 PMC: 9916680. DOI: 10.3390/ijms24032606.

Learning from small medical data-robust semi-supervised cancer prognosis classifier with Bayesian variational autoencoder.

Hsu T, Lin C Bioinform Adv. 2023; 3(1):vbac100.

PMID: 36698767 PMC: 9832968. DOI: 10.1093/bioadv/vbac100.

Shikonin reverses pyruvate kinase isoform M2-mediated propranolol resistance in infantile hemangioma through reactive oxygen species-induced autophagic dysfunction.

Yang E, Wang X, Huang S, Li M, Li Y, Geng Y Cancer Sci. 2022; 114(3):806-821.

PMID: 36369903 PMC: 9986094. DOI: 10.1111/cas.15649.

References

Georgoulias V, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A, Veslemes M . Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet. 2001; 357(9267):1478-84. DOI: 10.1016/S0140-6736(00)04644-4. View

Yang W, Xia Y, Ji H, Zheng Y, Liang J, Huang W . Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation. Nature. 2011; 480(7375):118-22. PMC: 3235705. DOI: 10.1038/nature10598. View

Schiller J, Harrington D, Belani C, Langer C, Sandler A, Krook J . Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346(2):92-8. DOI: 10.1056/NEJMoa011954. View

Mazurek S . Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol. 2010; 43(7):969-80. DOI: 10.1016/j.biocel.2010.02.005. View

David C, Chen M, Assanah M, Canoll P, Manley J . HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature. 2009; 463(7279):364-8. PMC: 2950088. DOI: 10.1038/nature08697. View

Kelland L . The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007; 7(8):573-84. DOI: 10.1038/nrc2167. View

Saridaki Z, Tzardi M, Papadaki C, Sfakianaki M, Pega F, Kalikaki A . Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients. PLoS One. 2011; 6(1):e15980. PMC: 3024325. DOI: 10.1371/journal.pone.0015980. View

Luo W, Semenza G . Emerging roles of PKM2 in cell metabolism and cancer progression. Trends Endocrinol Metab. 2012; 23(11):560-6. PMC: 3466350. DOI: 10.1016/j.tem.2012.06.010. View

Georgoulias V, Ardavanis A, Tsiafaki X, Agelidou A, Mixalopoulou P, Anagnostopoulou O . Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol. 2005; 23(13):2937-45. DOI: 10.1200/JCO.2005.04.016. View

10.

Siddik Z . Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003; 22(47):7265-79. DOI: 10.1038/sj.onc.1206933. View

11.

Hitosugi T, Kang S, Vander Heiden M, Chung T, Elf S, Lythgoe K . Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal. 2009; 2(97):ra73. PMC: 2812789. DOI: 10.1126/scisignal.2000431. View

12.

Yang W, Toffa S, Lohn J, Seifalian A, Winslet M . Malignant ascites increases the antioxidant ability of human ovarian (SKOV-3) and gastric adenocarcinoma (KATO-III) cells. Gynecol Oncol. 2005; 96(2):430-8. DOI: 10.1016/j.ygyno.2004.10.016. View

13.

Clower C, Chatterjee D, Wang Z, Cantley L, Vander Heiden M, Krainer A . The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism. Proc Natl Acad Sci U S A. 2010; 107(5):1894-9. PMC: 2838216. DOI: 10.1073/pnas.0914845107. View

14.

Postel-Vinay S, Vanhecke E, Olaussen K, Lord C, Ashworth A, Soria J . The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. Nat Rev Clin Oncol. 2012; 9(3):144-55. DOI: 10.1038/nrclinonc.2012.3. View

15.

Yang P, Ebbert J, Sun Z, Weinshilboum R . Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review. J Clin Oncol. 2006; 24(11):1761-9. DOI: 10.1200/JCO.2005.02.7110. View

16.

Christofk H, Vander Heiden M, Harris M, Ramanathan A, Gerszten R, Wei R . The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008; 452(7184):230-3. DOI: 10.1038/nature06734. View

17.

Yang W, Lu Z . Regulation and function of pyruvate kinase M2 in cancer. Cancer Lett. 2013; 339(2):153-8. PMC: 3950276. DOI: 10.1016/j.canlet.2013.06.008. View

18.

Yoo B, Ku J, Hong S, Shin Y, Park S, Kim H . Decreased pyruvate kinase M2 activity linked to cisplatin resistance in human gastric carcinoma cell lines. Int J Cancer. 2003; 108(4):532-9. DOI: 10.1002/ijc.11604. View

19.

Christofk H, Vander Heiden M, Wu N, Asara J, Cantley L . Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature. 2008; 452(7184):181-6. DOI: 10.1038/nature06667. View

20.

Noguchi T, Yamada K, Inoue H, Matsuda T, Tanaka T . The L- and R-type isozymes of rat pyruvate kinase are produced from a single gene by use of different promoters. J Biol Chem. 1987; 262(29):14366-71. View